Publications by authors named "G R Boniface"

Employment decision-making is essential for understanding workforce trends. Current occupational therapy workforce research describes distribution disparities of occupational therapists within geographic locations, services such as acute care or community health, and private or public sectors. New graduates of occupational therapy programs are critical to meeting the demand and distribution disparities of occupational therapy services in British Columbia.

View Article and Find Full Text PDF

In 2022, the World Health Organization (WHO) predicted that climate change would cause thousands of additional deaths per year from malnutrition, malaria, diarrhea, and heat stress alone between the years of 2030 and 2050. With such health consequences and environmental changes, climate change is impacting human occupations globally. However, there is a gap in the literature regarding the occupational therapists' role in climate change, particularly in the Canadian context.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to understand how therapists determine the intensity of hand strengthening exercises for patients with rheumatoid arthritis (RA) using specific clinical cues.
  • - Therapists analyzed 69 hypothetical patient scenarios and identified that the intensity prescribed was mainly influenced by the patient's reported pain intensity, disease activity, and recent hand pain.
  • - The findings revealed that consistent prescribers relied on fewer cues in their decision-making, highlighting the importance of pain and disease status in exercise recommendations for RA patients.
View Article and Find Full Text PDF

Introduction: Patients with chronic scrotal content pain (CSCP) lack effective, non-invasive treatment options. We aimed to determine the local and systemic safety, tolerability, pharmacokinetics (PK), and efficacy of a long-lasting local anesthetic in patients with CSCP.

Methods: This was a prospective, single-center, open-label, single-arm, phase 1, dose-escalating trial completed between October 2019 and March 2021.

View Article and Find Full Text PDF